Wang Hai-tao, Jiang Wei-liang, Zhang Ying-nan, Sun Zhan-feng, Sun Qing-feng, Ma Jun
Harbin Medical University, Harbin 150086, China.
Zhonghua Yi Xue Za Zhi. 2009 Dec 8;89(45):3181-5.
Multicentre clinical observation for therapeutic efficacy and clinical safety of anticoagulation and thrombolysis in deep venous thrombosis (DVT).
127 patients with DVT in left leg were randomly divided into four groups. Group A: treated with batroxobin. Group B: use Low Molecular Weight Heparin (LMWH). Group C: batroxobin and LMWH. Group D: urokinase and LMWH. Observing the perimeter of thigh and calf periodically, monitoring coagulation function, registering the frequency and degree of the complication.
All the treatments in four groups can relieve the swell level of the affected legs (P < 0.05). We got the best efficacy when we use batroxobin together with LMWH (P < 0.05), especially in treating the patients with a long course of treatment. Batroxobin can obviously reduce the level of blood FBG (P < 0.05), and have no significant effect with other index of coagulation function (P > 0.05). Inject ing batroxobin into affected legs with the micro pump got a better efficacy and much safer than intravenously guttae from peripheral vein.
Treating DVT with batroxobin got a definite efficacy, especially in cases with a long course of treatment; micro pumping can give a better effect and a high safety.
对抗凝及溶栓治疗下肢深静脉血栓形成（DVT）的疗效及临床安全性进行多中心临床观察。
将127例左下肢DVT患者随机分为四组。A组：用巴曲酶治疗；B组：用低分子肝素（LMWH）；C组：巴曲酶联合LMWH；D组：尿激酶联合LMWH。定期观察大腿及小腿周径，监测凝血功能，记录并发症发生的频率及程度。
四组治疗均能减轻患肢肿胀程度（P<0.05）。巴曲酶联合LMWH疗效最佳（P<0.05），尤其对于病程较长的患者。巴曲酶能明显降低血纤维蛋白原（FBG）水平（P<0.05），对其他凝血功能指标无明显影响（P>0.05）。用微量泵将巴曲酶注入患肢比从外周静脉静脉滴注疗效更好且更安全。
巴曲酶治疗DVT疗效确切，尤其对于病程较长者；微量泵给药效果更佳且安全性高。
